» Articles » PMID: 25313000

Pharmacologic Rescue of Motor and Sensory Function by the Neuroprotective Compound P7C3 Following Neonatal Nerve Injury

Overview
Journal Neuroscience
Specialty Neurology
Date 2014 Oct 15
PMID 25313000
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Nerve injuries cause pain, paralysis and numbness that can lead to major disability, and newborns often sustain nerve injuries during delivery that result in lifelong impairment. Without a pharmacologic agent to enhance functional recovery from these injuries, clinicians rely solely on surgery and rehabilitation to treat patients. Unfortunately, patient outcomes remain poor despite application of the most advanced microsurgical and rehabilitative techniques. We hypothesized that the detrimental effects of traumatic neonatal nerve injury could be mitigated with pharmacologic neuroprotection, and tested whether the novel neuroprotective agent P7C3 would block peripheral neuron cell death and enhance functional recovery in a rat neonatal nerve injury model. Administration of P7C3 after sciatic nerve crush injury doubled motor and sensory neuron survival, and also promoted axon regeneration in a dose-dependent manner. Treatment with P7C3 also enhanced behavioral and muscle functional recovery, and reversed pathological mobilization of spinal microglia after injury. Our findings suggest that the P7C3 family of neuroprotective compounds may provide a basis for the development of a new neuroprotective drug to enhance recovery following peripheral nerve injury.

Citing Articles

P7C3 suppresses astrocytic senescence to protect dopaminergic neurons: Implication in the mouse model of Parkinson's disease.

Chen Y, Zhu Z, Yan Y, Sun H, Wang G, Du X CNS Neurosci Ther. 2024; 30(7):e14819.

PMID: 39056208 PMC: 11273101. DOI: 10.1111/cns.14819.


Higher concentration of P7C3 than required for neuroprotection suppresses renal cell carcinoma growth and metastasis.

Shu G, Chen W, Huang C, Shan H, Ye J, Li J J Cancer. 2024; 15(5):1191-1202.

PMID: 38356717 PMC: 10861821. DOI: 10.7150/jca.90439.


Application of P7C3 Compounds to Investigating and Treating Acute and Chronic Traumatic Brain Injury.

Sridharan P, Miller E, Pieper A Neurotherapeutics. 2023; 20(6):1616-1628.

PMID: 37651054 PMC: 10684439. DOI: 10.1007/s13311-023-01427-8.


Current and future therapeutic strategies for Alzheimer's disease: an overview of drug development bottlenecks.

Peng Y, Jin H, Xue Y, Chen Q, Yao S, Du M Front Aging Neurosci. 2023; 15:1206572.

PMID: 37600514 PMC: 10438465. DOI: 10.3389/fnagi.2023.1206572.


Targeting NAD Metabolism for the Therapy of Age-Related Neurodegenerative Diseases.

Li F, Wu C, Wang G Neurosci Bull. 2023; 40(2):218-240.

PMID: 37253984 PMC: 10838897. DOI: 10.1007/s12264-023-01072-3.